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Eﬀects of a Kampo (Japanese herbal) medicine “shoseiryuto (SST, xiao-qing-long-tang in Chinese)”, which has been used for the
treatment of allergic bronchial asthma clinically, were examined on ovalbumin (OVA)-sensitized allergic airway inﬂammation
model (i.e., bronchial asthma) in a mouse. When SST was orally administered at 0.5gkg−1 day−1 from day 1 to 6 after OVA
inhalation, SST reduced the inﬂammation in lung tissue, the number of eosinophils and the OVA-speciﬁc immunoglobulin E
(IgE) antibody titer in bronchoalveolar lavage (BAL) ﬂuids at 7 days after the OVA inhalation. SST also reduced the airway
hyperreactivity at 6 days after the OVA inhalation. Proteomic analysis with the agarose two-dimensional electrophoresis showed
thattheexpressionofspectrin α2wasreducedinthelungtissueofOVA-sensitizedmiceandSSTrecovered theexpression.Western
blot and immunohistochemical analyses of lung tissue also conﬁrmed this result. When prednisolone was orally administered at
3mgkg −1 day−1 from day 1 to 6 after OVA inhalation, the inﬂammation in lung tissue, the number of eosinophils in BAL ﬂuids
and airway hyperreactivity were reduced in the OVA-sensitized mice. However, prednisolone did not reduce the OVA-speciﬁc IgE
antibody titer in BAL ﬂuids and did not recover the expression of spectrin α2 in lung tissue. These results suggest that at least a
part of action mechanism of SST against OVA-sensitized allergic airway inﬂammation in a mouse model is diﬀerent from that of
prednisolone.
1.Introduction
Dramatic increases in the prevalence of bronchial asthma
have occurred over the past few decades in Westernized
countries and more recently in less-developed nations [1].
Estimates suggest that as many as 300 million persons are
aﬀected worldwide. Allergic bronchial asthma is character-
ized by elevated serum immunoglobulin E (IgE) antibody
level and inﬂammation of the airways with recruitment of
eosinophils in bronchoalveolar lavage (BAL) ﬂuids [2–4].
Construction of airway smooth muscle and development
of airway hyper-reactivity (AHR) are also hallmarks of
bronchial asthma [4–6]. Shoseiryuto (SST, xiao-qing-long-
tang in Chinese and so-cheong-ryong-tang in Korea) is
a kind of Kampo (Japanese herbal) medicines and has
been used clinically for the treatment of allergic rhinitis,
bronchitis,bronchialasthma[7]andcoldsymptoms. In vitro
antiallergic activities of SST include inhibition of histamine
release and degranulation of mast cells [8, 9], proliferation
of eosinophils [10], growth and diﬀerentiation of basophils
[11], cholinergic eﬀects for nasal gland acinar cells [12],
synthesis of tumor necrosis factor α by peripheral blood
mononuclear cells [13] and contraction of bronchial smooth
muscle [14, 15]. In vivo antiallergic activities of SST include
inhibition of passive cutaneous anaphylaxis (PCA) in rat
[8, 16] and it showed eﬃcacies in animal models of allergic
rhinitis [17–19] and allergic asthma [20–22]. Previously, we
have reported that SST reduced the productions of Th22 Evidence-Based Complementary and Alternative Medicine
cell-associated cytokines, interleukin (IL)-4 and -5 [23, 24],
and restored production of the Th1 cell-associated cytokine,
interferon (IFN)-γ [23, 24], from lung CD4+ T cells and
BAL ﬂuid of ovalbumin (OVA)-sensitized allergic airway
inﬂammation in a mouse model [25]. We also reported
that anti-OVA IgE antibody levels were reduced in the BAL
ﬂuids of the sensitized mice after oral administration of SST
[25]. However, the mode of actions of anti-inﬂammatory
activity of SST against bronchial asthma remains to be fully
elucidated.
In present study, we further elucidate the action mech-
anism of SST on the treatment of bronchial asthma.
The in vivo eﬀects of SST in mice were investigated by
examining the AHR, recruitment of eosinophils and the
production of allergen-speciﬁc IgE antibody, and compared
with prednisolone using an OVA-sensitized allergic airway
inﬂammation model. In present study, we have also adopted
a proteomic analysis to identify lung protein(s) that are
aﬀected by SST treatment of the mouse model using
agarose two-dimensional (2D) gel electrophoresis and mass
spectrometry (MS)-based protein identiﬁcation.
2. Methods
2.1. Materials. Eight medicinal plants were used for prepa-
ration of a Kampo medicine, SST. Pinelliae Tuber (tuber
of Pinellia ternata) (lot no. TI302704, cultivated at Gansu
Province in China in 2001), Ephedrae Herba (stem of
Ephedra sinica) (lot no. 302423, cultivated at Inner Mongolia
and Hebei Province in China in 1998 and 1999), Schizandrae
Fructus (fruit of Schisandra chinensis) (lot no. 253109,
cultivatedatJilin Province in China in 2000), Paeoniae Radix
(root of Paeonia lactiﬂora) (lot no. YA302207, cultivated
at Nara Prefecture in Japan in 2001), Glycyrrhizae Radix
(root of Glycyrrhiza uralensis) (lot no. 253116, cultivated at
Inner Mongolia in China in 2000) and Zingiberis Siccatum
Rhizoma (scalded rhizoma of Zingiber oﬃcinale)( l o tn o .
302903, cultivated at Yunnan Province in China in 2001)
were purchased from Uchida Wakan-yaku (Tokyo, Japan).
Asiasari Radix (root of Asiasarum heterotropoides var. mand-
shuricum)(lotno.20007151,cultivatedatGangwonProvince
inKoreain2000)wasobtainedfromTsumura(Tokyo,Japan)
and Cinnamomi Cortex (bark of Cinnamomum cassia)
(lot no. 300801, cultivated in Vietnam in 2000) was from
Tochimoto Tenkaido (Osaka, Japan). A voucher specimen
of these plants was deposited at Laboratory of Biochemical
Pharmacology for Phytomedicines, Kitasato Institute for Life
Sciences,KitasatoUniversityinTokyo,Japan.SSTextractwas
prepared as previously described [25, 26]. Brieﬂy, a mixture
of Pinelliae Tuber (6g), Ephedrae Herba (3g), Schizandrae
Fructus(3g),CinnamomiCortex(3g),PaeoniaeRadix(3g),
Asiasari Radix (3g), Glycyrrhizae Radix (2g) and Zingiberis
Siccatum Rhizoma (1g) was extracted with 600mL of
water. After the extract was centrifuged at 7000×gf o r
30min, the supernatant was collected and lyophilized (yield,
19.1%). Prednisolone sodium succinate was purchased from
Shionogi&Co.Ltd.(Osaka,Japan).Rabbitanti-mousespec-
trin α2 antibody and anti-β-actin monoclonal antibody were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively.
2.2. Three-dimensional High Performance Liquid Chromatog-
raphy Analysis of SST Extract. The three-dimensional (3D)
high performance liquid chromatography (HPLC) analysis
of SST extract was performed as previously described
[25]. The 3D HPLC proﬁle of an aqueous SST extract is
shown in Figure 1. The analysis based on ultraviolet
(UV)-absorption clearly showed the presence of the
following major constituents in SST extract and the
content of each constituent was shown in parenthe-
sis: liquiritin (4.0μgmg −1 SST extract), liquiritigenin
(1.5μgmg −1) and glycyrrhizin (25.1μgmg −1) (originating
from Glycyrrhizae Radix); paeoniﬂorin (22.9μgmg −1)a n d
albiﬂorin (12.6μgmg −1) (Paeoniae Radix); cinnamalde-
hyde (0.4μgmg −1) and cinnamic acid (1.7μgmg −1) (Cin-
namomi Cortex); catechin (3.5μgmg −1) and ephedrine
(12.9μgmg −1) (Ephedrae Herba); schizandrin (0.2μgmg −1)
(Schisandrae Fructus); homogentisic acid (Pinelliae Tuber);
safrole (Asiasari Radix). Contents of homogentisic acid and
safrole in SST extract can not determined because each peak
was overlapped with more than one constituent on the 3D
HPLC proﬁle.
2.3. Animals. Five-week-old female BALB/c mice were pur-
chased from Japan SLC (Hamamatsu, Japan). The animals
were housed in plastic cages in an air-conditioned room
at 23 ± 2◦C with a relative humidity of 55 ± 10% under
a 12-h light-dark cycle, fed a standard laboratory diet and
given water ad libitum. Animal experiments were approved
by the Animal Research Committee of Kitasato University,
and performed in accordance with the Guidelines for Care
and Use of Laboratory Animals at Kitasato University and
the National Research Council Guide for the Care and Use of
Laboratory Animals in Japan.
2.4. Preparation of Allergic Airway Inﬂammation Model Mice.
Themouseallergicairwayinﬂammationmodelwasprepared
according to methods previously described [25–28]. Mice,
6-week-old, were sensitized by an intraperitoneal injection
of 0.5mL of alum-precipitated antigen containing 8μgo f
OVA (grade VI, Sigma-Aldrich) absorbed to 2mg of alum
(aluminium hydroxide hydrate gel, LSL) in saline vehicle.
A booster injection of this alum-OVA mixture was given
5 days later. Non-sensitized control animals received alum
only. Seven days after sensitization, the mice were exposed to
provocationofantigen.Forthechallengeofantigen,themice
were placed in a chamber (Sanki Kagaku Kogei, Kawasaki,
Japan) and were exposed twice to aerosolized OVA (0.5%) in
phosphate buﬀered saline (PBS) for 1h at 4h intervals. The
aerosolized OVA was produced by an ultrasonic nebulizer
(Model NE-U12, OMRON, Tokyo, Japan).
2.5. Airway Responsiveness. Airway responsiveness was as-
sessed with whole body plethysmograph (Buxco, Troy, NY,
USA). This system estimates total pulmonary airﬂow using a
dimensionless parameter known as enhanced pause (Penh).Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Chemical proﬁle of the hot water extract from shoseiryuto as analyzed by 3D HPLC.
Six days after the challenge with aerosolized OVA, mice were
placed in the chamber and exposed to methacholine chloride
(an acetylcholine receptor agonist, Sigma-Aldrich) in saline
for3minwithnebulizeratincreasingconcentrations(3.125–
50mgmL−1) for dose responsiveness. Airway responsiveness
was expressed as Penh value. Readings were taken for 5 min
following each nebulization.
2.6. Specimens. Mice were anesthetized with diethyl ether
and then bled from an axillary artery. Plasma was prepared
from the blood with EDTA-2K as anticoagulant by centrifu-
gation and used for titration of antibody. After bleeding,
mice were incised ventrally along the median line from the
xiphoid process to the point of the chin. The trachea with
lung attached was taken out and washed twice by inﬂating
the lung through the trachea with 2mL of PBS containing
0.1%bovineserumalbumin(BSA)and1mMEDTA-2K.The
BAL ﬂuid was used after the removal of cellular debris by
centrifugation at 1200×gf o r2 0m i na t4 ◦C. Eosinophils in
blood and BAL ﬂuid were stained with Hinkelman’s solution
and the number wascounted using a hemocytometer, Fuchs-
Rosenthal. Smear of blood or BAL cells on a glass slide
was stained with a May-Grunwald Giemsa stain. Diﬀerential
cell counting was performed using standard morphological
criteria in which 100 cells were counted per slide.
2.7. Lung Histology. After preparation of BAL ﬂuids, the
right lung was inﬂated with 1mL of 3.7% paraformaldehyde
and then ﬁxed in 3.7% paraformaldehyde for 2 days. After
ﬁxation, the right lung was embedded in paraﬃnw i t h
Tissue-Tek Inﬁltration Processor (Sakura Finetek Japan,
Tokyo, Japan) and 2μm sections were cut with Sledge
Microtome IVS-410 (Sakura Finetek Japan). Sections were
then mounted on glass slide and stained with hematoxylin
and eosin. Mucus production and goblet cell hyperplasia was
examined by periodic acid-Schiﬀ (PAS) staining.4 Evidence-Based Complementary and Alternative Medicine
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 2:Eﬀects ofSSTandprednisoloneonlungtissueeosinophilia, hypertrophiedsmoothmuscleandmucus secretioninOVA-sensitized
mice were measured. Non-sensitized BALB/c mice were treated p.o. with water (a and e), and OVA-sensitized mice were treated p.o. with
water (b and f), SST (0.5gkg−1) (c and g) or prednisolone (3mgkg−1) (d and h) ﬁve times from day 1 to 6 after OVA exposure. Lung tissues
were removed at 7 days after OVA exposure and stained with hematoxylin and eosin (a–d) or periodic acid-Schiﬀ (e–h) as described in
“Methods” section. Magniﬁcation ×100.
2.8. Enzyme Linked Immunosorbent Assay for Anti-OVA IgE
and IgG1 Antibodies. The OVA-speciﬁc IgE and IgG1 anti-
body titers in BAL ﬂuid and plasma were measured by the
modiﬁed ﬂuorometric reverse (antibody-capture) enzyme
linked immunosorbent assay (ELISA) [25, 29, 30]. Brieﬂy,
the wells of a 96-well ELISA plate (Immulon 4 HBX,
T h e r m oF i s h e rS c i e n t i ﬁ c ,R o c k f o r d ,I L ,U S A )w e r ec o a t e d
with 100μL of anti-mouse IgE or IgG1 mAb (BD Bio-
sciences Pharmingen, San Diego, CA, USA; 1μgmL −1)i n
50 mM carbonate-bicarbonate buﬀer (pH 9.5) containing
BSA (10μgmL −1). The plate was incubated at 37◦Cf o r3h .
After the solution was removed, the blocking solution, 1%
skimmed milk (Morinaga Milk Industry, Tokyo, Japan) in
PBS, was placed in each well (300μL) and incubated at
37◦C for 1h. The plates were washed four times with PBS
containing 0.05% Tween 20 (PBS-Tween). Serial dilutions
of BAL ﬂuid or plasma with SuperBlock blocking buﬀer
in PBS (Thermo Fisher Scientiﬁc) (diluted to 1:10 with
PBS and added Tween 20 to 0.05%) were added to the
wells (100μL). After being sealed with adhesive tape, the
plates were incubated overnight at room temperature. After
washing with PBS-Tween, biotinylated OVA (1μgmL −1)i n
the blocking solution was added to each well (100μL).
The plates were incubated at room temperature for 1h
with shaking on a microplate mixer. After washing the
wells, streptavidin-β-galactosidase conjugate (Calbiochem,Evidence-Based Complementary and Alternative Medicine 5
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Figure3:EﬀectsofSSTandprednisoloneonnumberofeosinophils
in blood and BAL ﬂuid of OVA-sensitized mice were measured.
OVA-sensitized mice were treated with SST, prednisolone (PRE) or
water as described in legend of Figure 2. Number of eosinophils in
blood (a) and BAL ﬂuid (b) were counted on 7 days after the OVA
exposure. Each column represents the mean ± SEM of ﬁve to seven
micepergroup.StatisticalanalysiswasconductedusingTukey’stest.
EMD Chemicals, Gibbstown, NJ), diluted to 1:1000 with
the blocking solution, was added (100μL) and incubated
at room temperature for 1h with shaking. After the
ﬁnal wash, 0.1mM 4-methylumbelliferyl-β-d-galactoside
(Sigma-Aldrich) in buﬀer A (10mM sodium phosphate
buﬀer, pH 7.0, containing 0.1M NaCl, 1mM MgCl2 and
0.1% BSA) was added to each well (100μL). The plates were
sealed with tape and then incubated at 37◦Cf o r2 h .T h e
enzyme reaction was stopped by the addition of 100μLo f
0.1M glycine-NaOH (pH 10.3), and the ﬂuorescence of the
4-methylumbelliferone measured (ex. 355nm, em. 460nm)
using a Fluoroskan II spectroﬂuorometer (Thermo Fisher
Scientiﬁc). Endpoint titers of OVA-speciﬁc IgE antibodies
were expressed as reciprocal log2 titers.
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Figure 4: Eﬀects of SST and prednisolone on diﬀerential cell
number in blood and BAL ﬂuid of OVAsensitized mice were
measured.OVA-sensitizedmiceweretreatedwithSST,prednisolone
(PRE) or water as described in legend of Figure 2.D i ﬀerential cell
number in blood (a) and BAL ﬂuid (b) were counted on 7 days
after the OVA exposure. Each column represents the mean ± SEM
of ﬁve to seven mice per group. #P<. 0001 versus control; ∗P<
.001 and ∗∗P<. 0001 versus water/OVA-sensitized group (Tukey’s
test). mac (macrophage), lym (lymphocyte), neu (neutrophil), eo
(eosinophil), baso (basophil), mono (monocyte).
2.9. Proteomic Analysis with Agarose 2D Electrophoresis
2.9.1. Sample Preparation. T h em i c ew e r es a c r i ﬁ c e du n d e r
light ether anesthesia, and the lungs were excised and
stored at −80◦C. Frozen tissues (∼20mg) were cut into
small pieces and disrupted using a Teﬂon glass homoge-
nizer in 20 volumes of 7M urea, 2M thiourea, 2% w/v
CHAPS, 0.1M dithiothreitol, 2.5% w/v Pharmalyte pH 3–
10(GEHealthcare,Buckinghamshire,England)andprotease
inhibitors (Complete Mini EDTA-free; Roche Diagnostics,
Mannheim, Germany), and then sonicated with Bioruptor
UCD-200T(CosmoBio,Tokyo,Japan).Thehomogenatewas6 Evidence-Based Complementary and Alternative Medicine
centrifuged at 112000×ga t4 ◦C for 30min, and the clear
supernatant was subjected to agarose 2D electrophoresis.
2.9.2. Agarose 2D Electrophoresis. Two-dimensional electro-
phoresis was performed according to the procedure given by
Oh-Ishi et al. [31–33]. Agarose gel was used for the ﬁrst-
dimension isoelectric focusing (IEF) and SDS-PAGE was for
the second-dimension electrophoresis. The ﬁrst-dimension
agarose gel was 180mm in length and 3.4mm in diameter
in a glass tube. The second-dimension polyacrylamide gel
was 11% T homogeneous slab gel, and was 200 (width) ×
120 (height) × 1.3mm. Sample solutions (∼100μL) were
subjected to the ﬁrst-dimension IEF at 12000Vh at 4◦C,
followed by ﬁxation in 10% trichloroacetic acid and 5%
sulfosalicylic acid for 1h at room temperature (RT). After
washing with water for 1h, the second-dimensional SDS-
PAGE was performed. Slab gels were stained with Coomassie
Brilliant Blue (CBB, PhastGel Blue R-350, GE Healthcare)
and destained in 30% v/v methanol containing 10% v/v
acetic acid.
2.9.3. Identiﬁcation of Proteins Separated by 2D Electrophore-
sis. Protein separated by agarose 2D electrophoresis was
identiﬁed by in-gel tryptic digestion of the protein followed
by mass spectrometry (MS). Protein separated by agarose
2D electrophoresis was fragmented into peptides using an
in-gel tryptic digestion. Protein spot in CBB stained 2D
electrophoresis gel was excised in squares of ∼1mm per
side, destained in 50% v/v acetonitrile (AcCN) containing
50mM NH4HCO3 and then washed with deionized water.
The gel pieces were dehydrated in 100% AcCN for 15min
and dried in a SpeedVac Evaporator (Waken-yaku, Kyoto,
Japan) for 45min. The pieces were rehydrated in 10–
30μL of 25mM Tris-HCl (pH 9.0) containing 25ngμL−1
trypsin (Sequencing Grade, Roche Diagnostics) for 45min
at 4◦C. Excess trypsin was discarded and the gel pieces were
incubated for 18h at 37◦C in a minimal volume (10–20μL)
of 50mM Tris-HCl (pH 9.0). Peptide fragments digested
in gel pieces diﬀused into the surrounding solution over
18h.Thesolutionwasslowlytransferredto1.5mlsiliconized
plastic test tubes and stored at 4◦C. Peptide fragments
remaining in gel pieces were further recovered after 20min
incubations at RT in minimal volumes of 5% v/v formic acid
containing50%v/vAcCN.Thesolutionscontainingpeptides
were pooled in siliconized tubes at 4◦C. Molar quantities
of recovered peptide fragments were estimated from the
staining intensity of the 2D electrophoresis spots that were
digested in-gel with trypsin. Digested peptides equivalent
to 10–20pmol of protein in 2D electrophoresis spots were
injected into a 30 × 2.1mm C8 RP column (Aquapore RP-
300; Perkin Elmer, Norwalk, CT, USA) attached to a HPLC
system (Nanospace SI-2; Shiseido Fine Chemicals, Tokyo,
Japan). The column temperature was 45◦C, and the ﬂow
rate of the mobile phase was 200μLmin −1. The solvent
compositionofthemobilephasewasprogrammedtochange
in 55min cycles with varying mixing ratios (r)o fs o l v e n t
A (0.05% v/v formic acid) to solvent B (90% v/v AcCN
and 0.05% v/v formic acid). The program for one cycle
of a solvent composition change was as follows: constant
mixing ratio r = 0% from time t = 0–5min, linear gradient
of r = 0–10% from t = 5–5.5min, linear gradient of r =
10–50% from t = 5.5–30min, linear gradient of r = 50–
80% from t = 30–32min, constant r = 80% from t = 32–
36min, downward linear gradient of r = 80–0% from t
= 36–37min and constant r = 0% from t = 37–55min.
Puriﬁed peptides were introduced from HPLC to an LCQ-
DECA (ThermoQuest, San Jose, CA, USA), an ion trap mass
spectrometer (ITMS), via an attached metal API2 needle
(an ESI adapter). The MS and MS/MS peptide spectra
were measured in a data dependent manner according
to the manufacturer’s operating speciﬁcations. SEQUEST
was used to identify proteins from the MS and MS/MS
spectra of peptides. This program searches entries in protein
sequence databases by computing and reporting a SEQUEST
score from the comparison. SEQUEST referred to the nr.Z
and Swiss-Prot.Z protein sequence databases downloaded
from ftp://ftp.ncbi.nih.gov/blast/db/. When the top ranked
candidates had SEQUEST scores lower than 100 or when
the top SEQUEST score was computed by using fewer than
10 peptide fragments, the raw MS and MS/MS spectra of
peptides were inspected to judge their qualities. When the
m/z ratios of the major peaks of the MS/MS spectra were
correspondedtothoseofthey-orb-seriesofpeakscalculated
from the amino acid sequences of candidate peptides, the
protein was identiﬁed.
2.10.WesternBlotting. Expressionofproteinwasdetermined
by immunoblotting as previously described [34] with minor
modiﬁcation. In brief, the left lung was cut into small
pieces and disrupted using a Teﬂon glass homogenizer in 20
volumes of 7M urea, 2M thiourea, 2% w/v CHAPS, 0.1M
DTT, 2.5% w/v Pharmalyte pH 3–10 and Complete Mini
EDTA-free, and then sonicated for 10s. The homogenate
was centrifuged at 112000×ga t4 ◦C for 30min, and the
clear supernatant was mixed with SDS sample buﬀer, boiled
for 5min and subjected to SDS-PAGE. Equal amounts of
lysate protein were run on a 7.5% SDS polyacrylamide gel
and transferred to nitrocellulose membranes (Hybond-ECL,
GE Healthcare). Nitrocellulose blots were blocked with 1%
BSA (Blot Qualiﬁed, Promega Corp., Madison, WI, USA)
in Tris-buﬀered saline (TBS), and then incubated with anti-
mousespectrinα2(1:200)andanti-β-actin(1:5000)inTBS
containing1%BSA.AfterwashingwithTBScontaining0.1%
Triton X-100 (TBST), the blots were incubated for 1h with
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(Cell Signaling Technology, Beverly, MA, USA) at a dilution
of 1:2000. Immunoreactive spectrin α2 protein was detected
withtheenhancedchemiluminescentprotocol(PerkinElmer
Life Sciences, Waltham, MA, USA).
2.11. Immunohistochemistry. For spectrin α2i m m u n o h i s -
tochemistry, lung sections on glass slides (MAS-GP type
A) were deparaﬃnized and washed with water, followed
by incubation in 3% H2O2/80% methanol for 20min at
RT to remove the endogenous peroxidase. After washing in
PBS containing 0.3% Triton X-100 (PBS-T), sections wereEvidence-Based Complementary and Alternative Medicine 7
blocked for 3h with 1% BSA in PBS-T, and then incubated
for overnight at 4◦C with rabbit anti-mouse spectrin α2
antibody (1:200). The sections were subsequently rinsed in
PBS-T,incubatedfor3hatRTwithbiotinylateddonkeyanti-
rabbit IgG (1:200, Molecular Probes, Eugene, OR, USA),
andincubatedfor3hatRTwithavidin-biotincomplexusing
the ABC kit (Vector Laboratories, Burlingame, CA, USA).
Spectrin α2-positive cells were visualized by incubating
sections with diaminobenzidine (DAB) solution (Vector
DAB, Vector Laboratories) as the chromogen, which results
in a brown reaction product. Sections were dehydrated, pen-
etrated and coverslipped using Permount (Fisher Scientiﬁc
International Inc., Fair Lawn, NJ, USA).
2.12. Statistical Analysis. All data were expressed as the
mean ± standard error of the mean (SEM). Results were
analyzed by one-way analysis of variance (ANOVA). Post hoc
comparisons, if applicable, were carried out using Fisher’s
Protected Least Signiﬁcant Diﬀerence (PLSD), Dunnett’s or
Tukey’stests.P-values<.05(P<. 05)wereconsideredindica-
tive of signiﬁcance.
3. Results
3.1. Histochemical Analysis of Eﬃcacy of SST on Lung Inﬂam-
mation. OVA-sensitization induced marked inﬁltration of
inﬂammatory cells, especially eosinophils, into the lamina
propria, and perivascular and peribronchiolar areas as
compared to non-sensitized and OVA-challenged control
mice (Figures 2(a) and 2(b)). Oral administration of SST or
prednisolone each attenuated the eosinophil-rich leukocyte
inﬁltration compared with vehicle control (Figures 2(c)
and 2(d)). On the other hand, OVA-sensitized and OVA-
challengedmice,butnotnon-sensitizedandOVA-challenged
mice developed marked goblet cell hyperplasia and mucus
hypersecretion within the bronchi in the lung (Figures
2(e) and 2(f)). The OVA-induced mucus secretion was
signiﬁcantly abated by SST and prednisolone compared to
vehicle control (Figures 2(g) and 2(h)). These results suggest
that SST and prednisolone decrease the inﬂammation in the
lung of the OVA-sensitized and OVA-challenged mice on
histochemical analysis.
3.2. Reduction of the Number and Percentage of Eosinophils by
SST. The OVA-sensitized and OVA-challenged mice had sig-
niﬁcantly increased the eosinophil counts in blood and BAL
ﬂuid as compared to non-sensitized and OVA-challenged
control mice (Figure 3). The percentage of eosinophils in
blood and BAL ﬂuid on lymphocyte count was also sig-
niﬁcantly elevated in OVA-sensitized and OVA-challenged
mice (Figure 4). The administration of SST or prednisolone
signiﬁcantly reduced the eosinophil counts and percentage
of eosinophils in blood (Figures 3(a) and 4(a))a n dB A L
ﬂuid (Figures 3(b) and 4(b)) as compared to vehicle control.
These results suggest that SST and prednisolone reduce
the circulation of eosinophils in blood and inﬁltration of
eosinophils in bronchoalveolar cavity of the OVA-sensitized
and OVA-challenged mice.
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Figure 5: Eﬀects of SST and prednisolone on OVA-speciﬁc IgE
antibody titers in OVA-sensitized mice were measured. OVA-
sensitized mice were treated with SST, prednisolone (PRE) or water
a sd e s c r i b e di nl e g e n do fFigure 2. OVA-speciﬁc IgE antibody titers
in plasma (a) and BAL ﬂuid (b) were determined at 7 days after
OVA exposure. Each column represents the mean ± SEM of ﬁve to
six mice per group. Statistical analysis was conducted using Tukey’s
test.
3.3. Inhibition of Anti-OVA IgE Antibody Production by SST.
Eﬀect of oral administration of SST on the anti-OVA IgE
and IgG1 antibody titers was examined in the plasma and
BAL ﬂuid of OVA-sensitized mice as an airway inﬂammation
model. Anti-OVA IgE antibody titers in the plasma and
BAL ﬂuid of the sensitized mice were signiﬁcantly higher
than those in the non-sensitized control at 7 days after the
inhalation (Figure 5). Anti-OVA IgG1 antibody titers in the
plasma and BAL ﬂuid of OVA-sensitized mice were also
signiﬁcantly higher than those from control mice (data not
shown). When SST or prednisolone was administered to
the OVA-sensitized mice, anti-OVA IgG1 antibody titers in
the plasma and BAL ﬂuid were not aﬀected at 7days after8 Evidence-Based Complementary and Alternative Medicine
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Figure 6:EﬀectsofSSTandprednisoloneonairwayhyperreactivity
(AHR) in OVA-sensitized mice were measured with plethysmogra-
phy. Non-sensitized mice were treated with water (closed circle),
and OVA-sensitized mice were treated with SST (closed inverted
triangle), prednisolone (open inverted triangle) or water (open
circle) as described in legend of Figure 2. AHR to aerosolized
methacholine (MeCh) was measured in unrestrained conscious
mice at 1h after the ﬁnal treatment of drug. Mice were placed into
the main chamber and were nebulized with PBS or MeCh (3.125,
6.25, 12.5, 25, 50mg ml−1) for 3min. Recording of Penh was taken
for 5min after each MeCh nebulization. Each bar represents the
mean ± S E Mo ff o u rm i c ep e rg r o u p .#P<. 05, ##P<. 01 and
###P<. 001 versus water/non-sensitized group (Fisher’s PLSD test).
∗P<. 05, ∗∗P<. 01 and ∗∗∗P<. 001 versus water/OVA-sensitized
group (Dunnett’s test).
the inhalation (data not shown). However, anti-OVA IgE
antibody titers in the plasma and BAL ﬂuid were decreased
signiﬁcantly by the administration of SST in comparison
with that of water-administered sensitized mice at 7days
after the inhalation (Figure 5). Unexpectedly, prednisolone
did not decrease the anti-OVA IgE antibody titers in
comparison with that of water-administered sensitized mice
at 7days (Figure 5). These results suggest that SST decreases
OVA-speciﬁc IgE antibody levels in BAL ﬂuid and plasma,
but prednisolone does not decrease the IgE antibody levels of
the sensitized mice.
3.4. Reduction of AHR by SST. The intraperitoneal sen-
sitization and nebulized provocation of mice with OVA
resulted in a dose-dependent increase in airway responsive-
ness to inhaled methacholine at 6days after the inhalation
(Figure 6). When SST or prednisolone was administered to
the OVA-sensitized mice, the AHR was suppressed signiﬁ-
cantly at 6days after the inhalation (Figure 6). These results
suggest that SST and prednisolone decrease the AHR of the
OVA-sensitized mice.
3.5. Two-dimensional Electrophoresis Analysis of Lung Tissue
from OVA-sensitized Mice. The eﬀect of SST extract was
compared at the doses of 0.1 and 0.5gkg−1 day−1 against
OVA-speciﬁc IgE Ab titers in the airway inﬂammation in
a mouse model. SST extract reduced the OVA-speciﬁc IgE
antibody titers in BAL ﬂuid signiﬁcantly at 0.5gkg−1 day−1
but not at 0.1gkg−1 day−1 (unpublished data). Therefore
proteomic analyses of lung tissues were performed from
the mice administered SST extract at 0.5gkg−1 day−1.E a c h
lungtissuesamplesfromnon-sensitizedandOVA-challenged
treated with water vehicle (n = 4), OVA-sensitized and OVA-
challenged treated with water vehicle (n = 4), non-sensitized
and OVA-challenged treated with SST (n = 4), and OVA-
sensitized and OVA-challenged treated with SST (n = 4) were
compared protein spots each other by 2D electrophoresis.
Among the all protein spots in 2D electrophoresis, OVA-
sensitization (Figure 7(b)) altered the expression level of
single protein species in lung tissue compared with non-
sensitized mouse (Figures 7(a) and 7(e)). SST treatment did
not aﬀect the expression of protein on non-sensitized mouse
(Figure 7(b)), but SST recovered the expression of protein
level that was changed by OVA-sensitization in lung tissue
(Figures 7(d) and 7(e)). This protein was identiﬁed as spec-
trin α2 by in-gel tryptic digestion of the protein followed by
MS (database accession No. gi|51706071|ref|XP 207079.3;
experimental MW, >200kDa theoretical MW, 209329Da;
SEQ score, 266.0; coverage, 17.2%).
3.6. Immunoblotting of Spectrin α2 in Lung. To verify the
2D electrophoresis ﬁndings, we conducted immunoblotting
on a selected protein target. Western blotting of lung tissue
using antibody targeted at spectrin α2 revealed that SST
signiﬁcantly up-regulated the reduced spectrin α2l e v e li n
OVA-sensitized mice (Figure 8). However, prednisolone did
not up-regulate the expression of spectrin α2i nt h el u n g
tissue of OVA-sensitized mice (Figure 8).
3.7. Recovery of Spectrin α2 Expression in the Lung by
SST. Compared with non-sensitized mice (Figure 9(a)),
OVA-sensitization resulted in the decrease of spectrin α2
expression in the type I alveolar epithelial cell membrane
(Figure 9(b)), indicating that spectrin α2 expression in theEvidence-Based Complementary and Alternative Medicine 9
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Figure 7: Eﬀect of SST on protein expression in lung tissues of OVA-sentitized mice was measured by agarose 2D electrophoresis. OVA-
sensitized or non-sensitized mouse was treated with SST or water as described in legend of Figure 2. Lung tissue was obtained at 7 day after
the OVA exposure. Agarose 2D electrophoresis patterns of non-sensitized/water-treated mouse (a), OVA-sensitized/water-treated mouse (b),
non-sensitized/SST-treated mouse (c) and OVA-sensitized/SST-treated mouse (d), and results of statistical analysis of spectrin α2 expression
(e). Each column represents the mean ± SEM of four mice per group. Statistical analysis was conducted using Tukey’s test.
type I alveolar epithelial cell membrane of airway inﬂamma-
tion model mice may be down-regulated by the sensitization
of OVA. Administration of SST increased the expression
of spectrin α2( Figure 9(c)) as compared to the water-
administeredcontrol(Figure 9(b)).However,administration
of prednisolone did not recover the expression of spectrin α2
(Figure 9(d)).
4. Discussion
Bronchial asthma is a chronic inﬂammatory disease of the
airways. Non-speciﬁc AHR, inﬁltration of inﬂammatory
cells, and airway edema are the main features of bronchial
asthma. The obstruction of the airway was also caused by
hyperplasia of goblet cells and hypersecretion of mucus
followed by dyspnea with wheezing, main features of
bronchial asthma. Eosinophils are predominant among the
inﬂammatory cells inﬁltrating the airways, and play a critical
role in the pathogenesis of bronchial asthma. Thus, one
therapeutic strategy for bronchial asthma would be to target
the mechanisms involved in the accumulation and activation
of eosinophils in the airways. Glucocorticosteroids are
currently the most eﬀective drugs available for treating the
airway inﬂammation of asthma. Corticosteroid treatment
reduces the number and activity of inﬁltrating inﬂammatory10 Evidence-Based Complementary and Alternative Medicine
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Figure 8:EﬀectsofSSTandprednisoloneonspectrinα2expression
level in lung tissue of OVA-sensitized mice were measured by
western blot analysis. OVA-sensitized mice were treated with SST,
prednisolone (PRE) or water as described in legend of Figure 2.
Lung tissue was obtained at 7 day after the OVA exposure. Western
blot with β-actin was performed to verify that equivalent amounts
of proteins were loaded in each lane. Western blotting patterns
of spectrin α2a n dβ-actin (a), and results of statistical analysis
of spectrin α2/β-actin ratio (b). Each column represents the
mean ± SEM of ﬁve to seven mice per group. Statistical analysis
was conducted using Tukey’s test.
cells, particularly eosinophils, and damps microvascular
leakage and other signs of inﬂammatory response [1, 35].
Glucocorticosteroids, however, induce signiﬁcant systemic
adverse eﬀects when given for prolonged periods. Therefore,
a safe alternative anti-asthmatic agent to corticosteroids is
needed in the management of bronchial asthma.
SST has been widely used clinically for the treatment
of allergic airway diseases including bronchial asthma and
allergic rhinitis in Japan. The action mechanism of SST
in allergic airway diseases has been studied in vitro and
in vivo. However, its mode of action is still not fully
elucidated for bronchial asthma. We have been reported SST
reduced the OVA-speciﬁc IgE antibody titer in BAL ﬂuids
and the production of IL-4 and IL-5 in CD4+ Tc e l l sf r o m
lung of the OVA-induced allergic airway inﬂammation in
a mouse model, and recovered the production of IFN-γ in
the T cells [25,F i g u r e1 0 ] .I nt h ep r e s e n ts t u d y ,m o d eo f
action of SST was further studied using OVA-induced airway
inﬂammation in a mouse model (Figure 10)a n dc o m p a r e d
with a glucocorticosteroid, prednisolone.
Oral administration of SST reduced the inﬁltration of
eosinophils, hypertrophy of smooth muscle and hyperplasia
of goblet cells in lung tissue of OVA-induced airway inﬂam-
mation in a mouse model (Figure 2). SST also signiﬁcantly
reduced the number of eosinophils in blood and BAL
ﬂuid of the mouse model (Figures 3 and 4). These results
suggest that SST shows the anti-inﬂammatory eﬀects in the
respiratory tracts of bronchial asthma through the reduction
of the number of eosinophils in blood and inﬁltration of
eosinophils into bronchoalveolar cavity. It has been reported
that various cytokines and chemokines, such as IL-5, IL-
13 and eotaxin, and so forth. are related to the number
and inﬁltration of eosinophils [4, 36]. Previously we have
reported that SST reduced the production of IL-5 in CD4+ T
cellsfromlungoftheairwayinﬂammationinamousemodel
[25]. These results suggest that SST reduced the inﬁltration
of eosinophils through the reduction of IL-5 in lung tissue.
Study on eﬀects of SST for other cytokines and chemokines
arenowinprogress.SSTsigniﬁcantlyreducedtheAHRofthe
airway inﬂammation in a mouse model (Figure 6). The AHR
is a main future of bronchial asthma and causes the dyspnea
against non-speciﬁc stimuli to respiratory tracts. SST may
decreasesymptomsinbronchialasthmapatientsthroughthe
reduction of AHR.
In present study, anti-OVA IgE antibody levels were
reduced by oral administration of SST both in the plasma
and BAL ﬂuids of the airway inﬂammation model mouse
(Figure 5). Omalizumab is a humanized monoclonal anti-
IgE antibody recently approved for the treatment of allergic
asthma, and inhibits allergic responses by binding to serum
IgE, thus preventing their interactions with cellular IgE
receptors [37]. The reduction of allergen-speciﬁc IgE anti-
body may be related to the eﬃcacy of SST against bronchial
asthma.Inpresentstudy,anti-OVAIgG1 antibodylevelswere
notaﬀectedbyoraladministrationofSSTbothintheplasma
and BAL ﬂuids of the airway inﬂammation model mouse. It
has been reported that serum IgG antibody can gain access
to mucosal surfaces by passive diﬀusion [38]. Ito et al. [39]
also reported that the serum IgG antibody move to the
surface of the tracheal, bronchial and bronchiolar mucosa
at a constant rate by diﬀusion. These results indicate that
OVA-speciﬁc IgG1 antibody in BAL ﬂuids may be originated
fromtheserumOVA-speciﬁcIgG1 antibody. Therefore it was
suggested that SST showed little eﬀect against production of
OVA-speciﬁc IgG1 antibody on humoral immune response.
Proteomic analysis with agarose 2D electrophoresis
shows expression of spectrin α2, a high molecular weight
protein (∼240kDa), was down-regulated in the lung tissue
of airway inﬂammation model mouse, and the expression
was recovered by administration of SST (Figure 7). These
results were conﬁrmed by western blotting of lung tissues
(Figure 8) .R o he ta l .[ 40] reported that proteomic analysis
of lung tissues from OVA-induced airway inﬂammation
in a mouse model, and the expressions of 11 spots were
signiﬁcantly changed in the mouse model compared with
OVA-sensitized and non-challenged control at 48h after the
last OVA exposure. Whereas, the expression of one spot,
spectrin α2, in lung tissues was signiﬁcantly changed in the
OVA-induced airway inﬂammation mouse model comparedEvidence-Based Complementary and Alternative Medicine 11
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Figure 9:EﬀectsofSSTandprednisoloneonspectrina2expressioninlungofOVA-sensitizedmiceweremeasuredbyimmunohistochemical
staining. The spectrin a2 was stained with antispectrin a2 antibody. OVA-sensitized mice were treated with SST, prednisolone or water as
described in legend of Figure 2. Lung tissue was obtained at 7 day after the OVA exposure. (a) Non-sensitized/water-treated mouse, (b) OVA-
sensitized/watertreated mouse, (c) OVA-sensitized/SST-treated mouse and (d) OVA-sensitized/prednisolone-treated mouse. Magniﬁcation
×200.
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Figure 10: Hypothetical diagram of therapeutic eﬀects of SST on airway inﬂammation.
with non-sensitized control at 7 days after the last OVA
exposure by proteomic analysis in present study (Figure 7).
The diﬀerence may be caused by the duration from OVA-
inhalation. Acute change of protein expressions observed at
48h after the last OVA exposure may be subsided within 7
days. Immunohistochemical analysis of lung tissues indicates
that the expression of spectrin α2w a sr e d u c e di nt h et y p e
I alveolar epithelial cell membrane of airway inﬂammation
model mouse, and the expression was recovered by admin-
istration of SST (Figure 9). Spectrin, an α/β heterodimer, is
oneofthemajorcomponentsofthecorticalcytoskeletonthat
lies beneath the plasma membrane [41]. It will be necessary
to examine the relation among the expression of spectrin α2,
bronchial asthma and pharmacological eﬀects of SST in the
future.
In present study, prednisolone, a corticosteroid, reduced
theinﬁltrationofeosinophils,hypertrophyofsmoothmuscle
and hyperplasia of goblet cells in lung tissue of OVA-induced
airway inﬂammation in a mouse model (Figure 2). Pred-
nisolonealsosigniﬁcantlyreducedthenumberofeosinophils12 Evidence-Based Complementary and Alternative Medicine
in blood and BAL ﬂuid, and the airway hyperreactivity of
the mouse model (Figures 3 and 4). These results indicate
that prednisolone has a potent anti-inﬂammatory activity
in present airway inﬂammation in a mouse model. SST
signiﬁcantly reduced the allergen-speciﬁc IgE antibody in
BAL ﬂuid and plasma (Figure 5), and recovered the down-
regulation of spectrin α2 in the lung tissue in the mouse
model (Figures 7–9). Nevertheless, prednisolone did not
reduce the allergen-speciﬁc IgE antibody (Figure 5) and did
not recover the expression of spectrin α2 (Figures 8 and 9).
These results suggest that at least a part of action mechanism
of SST against airway inﬂammation is diﬀerent from that
of prednisolone. Ikeda et al. reported that prednisolone
reduced the OVA-speciﬁc IgE antibody in the serum in OVA-
sensitized nasal allergy model mice [21]. In this experiment,
oral administration of prednisolone was started at OVA-
sensitization of the mice. In present study, prednisolone
was orally administered only after the OVA-inhalation to
the mice. These results indicate that prednisolone may be
suppressed the OVA-sensitization step of the mice. Although
most patients with asthma respond to corticosteroid treat-
ment, small subsets of patients demonstrate persistent tissue
inﬂammation despite treatment with high doses [42]. This
corticosteroid resistance or failure results from interaction
between susceptibility genes and the host’s environment,
in addition to immunologic factors [42]. SST may be
eﬀective for the treatment of the corticosteroid-resistant
bronchial asthmatic patients through the diﬀerent mecha-
nismfromcorticosteroids.Itwillbenecessarytoexaminethe
eﬀectivenessofSSTtreatmentforthecorticosteroid-resistant
bronchial asthma in the future.
In previous paper, we have reported that pinellic acid
(9,12,13-trihydroxy-10E-octadecenoic acid) prepared from
the tuber of P. ternata Breitenbach, one component of
the herbs of SST [30], reduced the OVA-speciﬁc IgE
antibody titer in the BAL ﬂuids from the OVA-induced
airway inﬂammation in a mouse model [25]. This result
suggests the possibility that pinellic acid is related to the
diﬀerent mechanism between SST and prednisolone. Study
on identiﬁcation of active substance(s) from SST is now in
progress.
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